Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia.
It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura.
In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases.
Further, it develops tolerogenic therapies to treat autoimmune diseases.
The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 20, 24 | -10.50 Decreased by -7.40 K% | -0.88 Decreased by -1.09 K% |
| Mar 7, 24 | -0.07 Decreased by -275.00% | -0.04 Decreased by -75.00% |
| Nov 13, 23 | -0.06 Decreased by -20.00% | -0.06 |
| Aug 17, 23 | -0.07 Decreased by -216.67% | -0.08 Increased by +12.50% |
| May 4, 23 | -0.14 Decreased by -160.87% | -0.09 Decreased by -55.56% |
| Mar 2, 23 | 0.04 Increased by +33.33% | -0.07 Increased by +157.14% |
| Nov 3, 22 | -0.05 Increased by +68.75% | -0.01 Decreased by -400.00% |
| Aug 4, 22 | 0.06 Increased by +50.00% | -0.08 Increased by +175.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 6.55 M Decreased by -68.37% | -9.00 M Decreased by -14.05% | Decreased by -137.41% Decreased by -260.55% |
| Jun 30, 23 | 5.25 M Decreased by -86.63% | -11.39 M Decreased by -440.72% | Decreased by -216.94% Decreased by -2.65 K% |
| Mar 31, 23 | 5.94 M Decreased by -82.53% | -25.75 M Decreased by -155.05% | Decreased by -433.70% Decreased by -415.19% |
| Dec 31, 22 | 16.80 M Decreased by -43.90% | 5.89 M Decreased by -51.85% | Increased by +35.09% Decreased by -14.17% |
| Sep 30, 22 | 20.71 M Decreased by -15.22% | -7.89 M Increased by +55.89% | Decreased by -38.11% Increased by +47.97% |
| Jun 30, 22 | 39.27 M Increased by +99.73% | 3.34 M Decreased by -26.79% | Increased by +8.51% Decreased by -63.35% |
| Mar 31, 22 | 34.00 M Increased by +207.68% | 46.78 M Increased by +290.20% | Increased by +137.60% Increased by +161.82% |
| Dec 31, 21 | 29.94 M Increased by +150.50% | 12.24 M Increased by +179.24% | Increased by +40.88% Increased by +131.63% |